# Dr. Lal Path Labs (NSE: LALPATHLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LALPATHLAB · Pivot · prices to 22 Oct 2026

Dr. Lal Path Labs (NSE: LALPATHLAB) closed at ₹1,838.50 on 22 Oct 2026, up 0.46% on the day. With a market capitalisation of ₹30,820 Cr, it ranks 265th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 58× trailing earnings, against a return on equity of 20.1% in FY26. Over the past year the share price has risen 16.3%. Its 52-week range is ₹1,272.60 (23 Mar 2026) to ₹2,038.60 (16 Sep 2026); the last close is 9.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹798 Cr (+19.1% year on year) and net profit ₹171 Cr (+27.2%), on a consolidated basis. Promoters held 53.19% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,838.50 |
| Market cap | ₹30,820 Cr |
| P/E (trailing) | 58 |
| ROE | 20.1% (FY26) |
| ROCE | 26.8% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹2,038.60 (16 Sep 2026) |
| 52-week low | ₹1,272.60 (23 Mar 2026) |
| 1-year return | +16.3% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹798 Cr | +19.1% | ₹171 Cr | +27.2% | ₹10.15 |
| Q4 FY26 | ₹703 Cr | +16.6% | ₹132 Cr | −15.0% | ₹7.86 |
| Q3 FY26 | ₹660 Cr | +10.6% | ₹91 Cr | −6.8% | ₹5.42 |
| Q2 FY26 | ₹731 Cr | +10.7% | ₹152 Cr | +16.4% | ₹18.05 |
| Q1 FY26 | ₹670 Cr | +11.3% | ₹134 Cr | +24.3% | ₹15.88 |
| Q4 FY25 | ₹603 Cr | +10.5% | ₹156 Cr | +81.2% | ₹18.57 |
| Q3 FY25 | ₹597 Cr | +10.7% | ₹98 Cr | +19.3% | ₹11.60 |
| Q2 FY25 | ₹660 Cr | +9.8% | ₹131 Cr | +18.2% | ₹15.52 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,461 Cr | ₹492 Cr |
| FY24 | ₹2,227 Cr | ₹362 Cr |
| FY23 | ₹2,017 Cr | ₹241 Cr |
| FY22 | ₹2,087 Cr | ₹350 Cr |
| FY21 | ₹1,581 Cr | ₹296 Cr |
| FY20 | ₹1,330 Cr | ₹228 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 53.19%
- Foreign institutions: 17.36%
- Domestic institutions: 21.59%
- Non-institutions: 7.47%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,691.90 | ₹34,576 Cr | 42.4 | — |
| [Emcure Pharmaceuticals](https://app.pivotnow.in/stock/EMCURE) | ₹1,759.20 | ₹33,369 Cr | 145.1 | — |
| [Global Health](https://app.pivotnow.in/stock/MEDANTA) | ₹1,215.10 | ₹32,671 Cr | 58.9 | — |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,889.60 | ₹30,705 Cr | 144.8 | — |
| [Sai Life Sciences](https://app.pivotnow.in/stock/SAILIFE) | ₹1,396.80 | ₹29,652 Cr | 85.1 | — |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹671.30 | ₹28,195 Cr | 111.9 | — |

## Questions and answers

### What is the share price of Dr. Lal Path Labs today?

Dr. Lal Path Labs (NSE: LALPATHLAB) last closed at ₹1,838.50 on 22 Oct 2026. Its 52-week high is ₹2,038.60 and its 52-week low is ₹1,272.60.

### What is the market cap of Dr. Lal Path Labs?

Dr. Lal Path Labs' market capitalisation is ₹30,820 Cr (₹30,820 Cr) at the 22 Oct 2026 close, ranking 265th among the NSE companies Pivot tracks.

### What is the P/E ratio of Dr. Lal Path Labs?

Dr. Lal Path Labs trades at a trailing P/E of 58. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 111.9.

### What is the ROE and ROCE of Dr. Lal Path Labs?

Return on equity was 20.1% in FY26 and return on capital employed was 26.8% in FY26 (consolidated figures).

### Is Dr. Lal Path Labs a debt-free company?

Dr. Lal Path Labs is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Dr. Lal Path Labs' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Lal Path Labs reported revenue of ₹798 Cr, +19.1% year on year, and net profit of ₹171 Cr, +27.2% year on year.

### How has Dr. Lal Path Labs stock performed over the last year?

Dr. Lal Path Labs' share price has risen 16.3% over the past year, +8.2% over three months and −3.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Dr. Lal Path Labs?

As of 30 Jun 2026: promoters 53.19%, foreign institutions 17.36%, domestic institutions 21.59%, non-institutions 7.47%.

### Who are Dr. Lal Path Labs' competitors?

The listed Pharma & Healthcare companies closest to Dr. Lal Path Labs by market cap are Narayana Hrudayalaya, Emcure Pharmaceuticals, Global Health, Wockhardt, Sai Life Sciences and Krishna Institute of Medical Sciences.

### Is Dr. Lal Path Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Dr. Lal Path Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LALPATHLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.